Thyroid Eye Disease: Endocrinologist & Ophthalmologist Collaboration
- Close communication between endocrinologists and ophthalmologists is essential for optimal thyroid eye disease treatment, according to vivek R.
- during the initial evaluation and throughout treatment, sharing information about the patient's health status is crucial.
- Knowing the stage of thyroid management – whether the patient is euthyroid or if new strategies like radioactive iodine or thyroidectomy are planned – helps ophthalmologists tailor their...
The cornerstone of effective thyroid eye disease treatment lies in the dynamic collaboration between endocrinologists and ophthalmologists. This crucial partnership ensures patients receive comprehensive care by facilitating open communication, shared insights, and tailored treatment plans. Dr. Vivek R.Patel emphasizes the importance of this approach, highlighting how managing thyroid health, including addressing hyperthyroidism, directly impacts eye conditions and influences the course of action. From understanding the stage of thyroid management to navigating the complexities of related conditions like diabetes, this interdisciplinary teamwork optimizes outcomes. Discover how innovative treatments, such as teprotumumab, and ongoing clinical trials for IGF-1 and FcRn inhibition are reshaping the landscape for thyroid eye disease and improving patient care. News Directory 3 reports on the latest advancements in treatment methods. Discover what’s next in this evolving field.
Endocrinologists and Ophthalmologists Collaborate on Thyroid Eye Disease Treatment
Close communication between endocrinologists and ophthalmologists is essential for optimal thyroid eye disease treatment, according to vivek R. Patel, MD, professor of clinical ophthalmology at teh University of California, Irvine. Patel discussed the importance of this collaboration with Trevor Angell,MD,associate professor of clinical medicine at USC Keck School of Medicine.
during the initial evaluation and throughout treatment, sharing information about the patient’s health status is crucial. Patel noted that while hyperthyroidism may not always lead to severe thyroid eye disease, poorly controlled hyperthyroidism can exacerbate eye conditions.
Knowing the stage of thyroid management – whether the patient is euthyroid or if new strategies like radioactive iodine or thyroidectomy are planned – helps ophthalmologists tailor their treatment. Associated endocrine problems, such as diabetes, also influence treatment decisions, especially with newer therapies affecting hyperglycemia.
Patel said that understanding the systemic perspective and future treatment plans allows for parallel and influential care.
Treatment for thyroid eye disease is divided into two categories: severity and activity. Steroids and orbital radiation can calm inflammation during active phases. Surgery remains a viable option for severe but inactive cases, addressing proptosis and misalignment.
Newer treatments, like teprotumumab, have shown promise in improving both disease activity and severity. Clinical trials are exploring IGF-1 inhibition and FcRn inhibition, offering potential future treatment options.
Patel said, “This collaboration is really meant for us to communicate with each other, not only at the time of diagnosis, but throughout the treatment paradigm for these patients as it’s so individual.”
What’s next
Patel will further discuss thyroid eye disease at the USC Peter A. Singer Thyroid Symposium on May 31, 2025.